Glucose transporter type 1 deficiency syndrome: clinical aspects, diagnosis, and treatment

Gabriel M. Veneruzzoa, Mariana A. Loosb, Marisa Armenoc, Cristina N. Alonsoa, Roberto H. Caraballob

ABSTRACT

Glucose transporter type 1 deficiency with a typical onset is a genetic disorder associated with the SLC2A1 gene. Usually appears during the first years of life with severe developmental delay, drug-resistant epilepsy, and movement disorders. Diagnosis is suspected based on clinical manifestations and a low glucose level in cerebrospinal fluid, and should be confirmed by the molecular genetic study of the SLC2A1 gene.

As it is a rare disease with variable clinical expression, early diagnosis is often challenging for the healthcare team. Nevertheless, this is important because early implementation of ketogenic therapy will lead to control of the clinical manifestations and a better long-term prognosis.

Here we review the glucose transporter type 1 deficiency syndrome focusing on its clinical, biochemical, molecular, and therapeutic characteristics.

Key words: glucose transporter type 1, SLC2A1, dyskinesias, epilepsy, ketogenic diet.

doi: http://dx.doi.org/10.5546/aap.2022-02677.eng


* Laboratory of Genomics; b Department of Neurology; c Department of Nutrition. Hospital de Pediatria S.A.M.I.C. Prof. Dr. Juan P. Garrahan, City of Buenos Aires, Argentina.

Correspondence to Gabriel Veneruzzo: gabrielveneruzzo@gmail.com

Funding: None.

Conflict of interest: None.

Received: 4-5-2022
Accepted: 6-3-2022

This is an open access article under the Creative Commons Attribution—Noncommercial—Noderivatives license 4.0 International. Attribution - Allows reusers to copy and distribute the material in any medium or format so long as attribution is given to the creator. Noncommercial – Only noncommercial uses of the work are permitted. Noderivatives - No derivatives or adaptations of the work are permitted.
LIST OF ABBREVIATIONS
CSF: cerebrospinal fluid
CNS: central nervous system
GLUT1: glucose transporter type 1
GLUT1DS: glucose transporter type 1 deficiency syndrome
KD: ketogenic diet
KDT: ketogenic diet therapy
MAD: modified Atkins diet

INTRODUCTION
Glucose transporter type 1 deficiency syndrome is a neurometabolic disorder that usually appears in the first months of life and is secondary to deleterious sequence variants in the SLC2A1 gene. This gene encodes the glucose transporter type 1 (GLUT1), which is primarily responsible for the entry of glucose into the central nervous system (CNS). Loss of function of one of the SLC2A1 alleles has been found to affect glucose transport, causing the disease. The so-called classic phenotype accounts for the majority of cases reported in the literature. It is characterized by an onset in the first years of life, drug-resistant seizures, delayed psychomotor development, acquired microcephaly, spasticity, ataxia, and movement disorders. Since it was first described and because of the identification of the genetic cause, the phenotypic spectrum has expanded considerably. In recent decades, a diverse group of related epileptic syndromes has been recognized. Less severe forms have also been described, generally manifesting later in life. Historically, for patients with GLUT1DS there is a delay in the definitive diagnosis of 6 to 11 years. The low prevalence of the disorder in daily practice, its wide phenotypic heterogeneity, and the lack of access to molecular studies may be the main reasons for this delay. Early diagnosis is important to start the ketogenic diet (KD), the current treatment of choice, as soon as possible. Early initiation of the KD has been shown to improve seizure control and overall outcome. The aim of this study was to provide a literature review on GLUT1DS with a focus on its clinical, molecular, diagnostic, and therapeutic characteristics.

CURRENT SITUATION OF GLUT1DS IN THE WORLD AND IN ARGENTINA
In the literature, highly variable incidence rates have been proposed for GLUT1DS, ranging from 1 in 90,000 to 1 in 24,000 live births. The Interdisciplinary Ketogenic Diet Therapy Team of Hospital Garrahan is currently seeing 6 patients diagnosed with GLUT1DS and estimates that there are at least 30 confirmed cases in our country (unpublished data). There is a clear gap between the estimated number of patients countrywide and the expected number based on international statistics. Considering the current Argentine population and assuming that the local incidence is within the international range, we would expect between 450 and 1670 individuals with the disorder countrywide.

CLINICAL CHARACTERISTICS
GLUT1DS has a wide phenotypic spectrum, ranging from mild movement disorders to severe forms including encephalopathy, epilepsy, and delayed psychomotor development. The classical phenotype (MIM #606777) is the most frequent and accounts for 85% of cases reported. Patients classically present with early onset encephalopathy, drug-resistant seizure, delayed psychomotor development, and deceleration of head growth with acquired microcephaly. In addition, motor involvement, including ataxia, spasticity, and dystonia, is often observed.

In recent years, the phenotypic spectrum of non-classical forms has markedly expanded; there are late-onset cases with mild psychomotor involvement, pure epileptic syndromes such as myoclonic atonic epilepsy or early onset absence epilepsy, and even patients without epilepsy, in whom permanent and paroxysmal movement disorders are the predominant manifestations.

The most important clinical features are described below.

a. Epilepsy
GLUT1DS should be considered in the differential diagnosis of any patient presenting with early-onset epilepsy, especially when drug resistant, and associated movement disorders. Epileptic seizures have variable semiology and include focal and generalized seizures and even epileptic spasms. Seizures are the first clinical sign in most patients and the main clinical concern in the first years of life, although they tend to resolve later in life.

The interictal EEG is usually normal; however, according to age, different patterns may be observed: in infants, slowing and focal epileptiform activity is more frequent, while a generalized 2.5–
Hz spike-wave pattern is observed in children aged 2 years and older. An interesting feature, when present, is an abnormal preprandial EEG that improves with feeding as glucose is restored to the brain.\textsuperscript{33,34}

It is important to note that GLUT1DS may be associated with different epileptic syndromes, including early onset absence epilepsy (10%), myoclonic atonic epilepsy (5%), and idiopathic generalized epilepsy (1%).\textsuperscript{9,11-16}

b. Movement disorders
Movement disorders, whether or not associated with epilepsy, are suggestive of GLUT1DS.\textsuperscript{4,5,30} These may be continuous and/or paroxysmal, and may change in response to different stressors, such as fasting, infections, prolonged exercise, and anxiety, among other emotions.

After seizures, the second most common symptom at onset are paroxysmal eye-head movements.\textsuperscript{29,32,35} They are characterized by multidirectional and bilateral saccadic eye movements, usually accompanied by ipsilateral head movements.\textsuperscript{35} Paroxysmal exercise-induced dyskinesia, episodes of alternating hemiplegia, and intermittent ataxia are also frequent. Myoclonus is usually of epileptic origin, although startle, action, and postural myoclonus has been less frequently reported.

Paroxysmal movement disorders usually intensify over time or may even develop during adolescence and adulthood.\textsuperscript{30}

Persistent motor disorders may include spasticity, ataxia, and dystonia, which often result in gait disturbances. Chorea and tremor, though less frequently, may also be observed.\textsuperscript{4,5,8,36,37}

c. Psychomotor development and cognitive function
In patients with GLUT1DS, intellectual disability is highly variable. Language delay and expressive language difficulties are frequently observed, possibly associated with speech impairment, such as dysarthria, learning difficulties, and cognitive impairment. The latter may be mild, moderate, or severe, but without a characteristic neuropsychological profile.\textsuperscript{4,5,8,38} Cognitive impairment is usually proportional to the age of onset and the severity of the neurological manifestations.\textsuperscript{4,5,32,39}

Behavioral disturbances, attention deficit, hyperactivity disorder, and depression may also be observed.\textsuperscript{5,39,40}

d. Atypical manifestations
Atypical manifestations include writer’s cramps, intermittent ataxia, total body paralysis, parkinsonism, and nocturnal muscle cramps in the legs.\textsuperscript{41}

Less frequently, alternating hemiplegia of childhood, hemiplegic migraine, cyclic vomiting, and stroke-like episodes with transient hemiparesis, dysarthria, or aphasia have been described.\textsuperscript{17,42-44}

Another rare manifestation of GLUT1DS is hemolytic anemia.\textsuperscript{45-47}

e. Temporal pattern of clinical manifestations
Symptoms develop following a specific pattern according to the age and time of onset of the clinical manifestations: paroxysmal eye-head movements, along with seizures, are characteristic of onset in early infancy.\textsuperscript{29,35} Developmental delay becomes increasingly evident and is followed by ataxia and exertion-induced dystonia, among other movement abnormalities that develop over time. Movement abnormalities generally are the main symptoms in adolescence and adulthood.\textsuperscript{30,31} The time course of key clinical features of GLUT1DS is shown in Figure 1.

MECHANISM, MOLECULAR CHARACTERISTICS, AND INHERITANCE PATTERNS
GLUT1 is an integral membrane protein comprising 492 amino acids (Figure 2a). Its main function is to transport D-glucose between compartments (Figure 2b).\textsuperscript{2} It is mostly expressed in erythrocytes, placental stromal cells, glial cells, and blood-brain barrier endothelial cells, where it facilitates the passage of glucose from the peripheral circulation to the CNS.\textsuperscript{51-53}

The protein is encoded by the SLC2A1 gene, which is located on the short arm of chromosome 1 and consists of 10 coding exons (1 and 10 partially) (Figure 2c).\textsuperscript{54,55}

GLUT1DS occurs when, due to an alteration in the SLC2A1 gene, the quality or quantity of the GLUT1 protein is not sufficient to ensure adequate supply of glucose to the CNS, affecting neurological function and development.\textsuperscript{1,2} The severity of the clinical condition has been found to be inversely proportional to the residual GLUT1 activity and an activity lower than 25% is incompatible with life.\textsuperscript{38,56-58}

While most GLUT1DS patients have a \textit{de novo} heterozygous SLC2A1 variant, about 10% have
one parent who is a carrier of the variant and therefore have an autosomal dominant inheritance pattern.\textsuperscript{4,5,17,18,41,59,60} In addition, different cases of autosomal recessive inheritance have also been reported.\textsuperscript{5,56,61}

The deleterious variants associated with GLUT1DS are distributed throughout the SLC2A1 gene, although most are found on exon 4, and some aminoacids are altered more frequently than others (Figure 3).\textsuperscript{3–5,62}

Approximately 90\% of the variants reported in patients affected with GLUT1DS involve one or a few base pairs of the SLC2A1 gene.\textsuperscript{5,17} More rarely, cases with large deletions or duplications, which may even involve the whole gene, have been reported.\textsuperscript{5,17,65,66}

An association has been described between the pathogenic variant and the severity of the clinical condition, while no correlation has been found between the genotype and the response to the KD.\textsuperscript{4,5,23,38} Nevertheless, it is important to mention that GLUT1DS has a great phenotypic heterogeneity and even patients with the same genotype may have very different clinical features.\textsuperscript{5,59}

**DIAGNOSIS**

**a. Cerebrospinal fluid analysis**

Hypoglycorrhachia together with normal glucose levels is a distinctive biomarker for GLUT1DS.\textsuperscript{3,38,67} Approximately 90\% of patients have glucose levels below 40 mg/dL.\textsuperscript{57,67,68} Lumbar puncture should be performed after 4 to 6 hours of fasting to stabilize glucose levels in the cerebrospinal fluid (CSF).\textsuperscript{28,69} Peripheral blood glucose levels should be measured immediately before the lumbar puncture so that it is temporally related to glycorrhachia thus avoiding the hyperglycemia response to stress that may be associated with this maneuver.

The CSF/peripheral blood glucose ratio is also a useful diagnostic marker, being lower than 0.4 in most of the cases.\textsuperscript{3,67}

Patients with GLUT1DS have hypoglycorrhachia with normal or low CSF lactic acid levels, which helps to differentiate it from other conditions that are also associated with hypoglycorrhachia, such bacterial infections of the CNS and some mitochondrial conditions.\textsuperscript{70–72}

The CSF features reported in a group of 157 patients with GLUT1DS by Leen et al. are summarized in Table 1.\textsuperscript{68}

**b. Study of the SLC2A1 gene**

Sanger sequencing of the SLC2A1 gene is the molecular method of choice to characterize GLUT1DS. All 10 exons should be sequenced, including at least 10 specific flanking intronic bases of each of them. If sequencing is negative, gross deletions or duplications should be detected using a methodology sensitive to this type of variants, such as multiplex ligation-dependent probe amplification (MLPA).

---

**Figure 1. Schematic representation of the temporal pattern of main clinical manifestations in GLUT1DS patients**

Classical phenotype

Epilepsy

Abnormal movements

Eye-head movements

Infancy

Childhood

Adolescence/Adulthood

Very frequent: ++++.
Frequent: ++.
Moderately frequent: ++.
Rare: +.
Massive parallel sequencing and comparative genomic hybridization offer the advantage of studying the SLC2A1 gene together with a large number of genes, which may be useful for differential diagnosis purposes. Nevertheless, in Argentina, access to these types of techniques is still limited and their cost is high compared to the standard Sanger/MLPA combination.

**Figure 2. Characteristics of the SLC2A1 gene and GLUT1 protein**

![Diagram of GLUT1 protein and SLC2A1 gene](image)
Currently, Hospital Garrahan offers the standard strategy for studying the SLC2A1 gene to patients seen at the Department of Neurology who meet the clinical and CSF criteria for GLUT1DS.

Once the index case has been characterized and molecularly confirmed, it is advisable to perform genetic studies in the patient’s parents to rule out the familial source of the disease.60

A small percentage of patients with a clinical diagnosis of GLUT1DS will have a negative molecular study of the SLC2A1 gene.75 It is possible that, in these cases, the pathogenic variant is located in gene regions not routinely studied, such as the promoter and deep intronic regions.66,75,76 It has recently been proposed that pathogenic variants in other genes could cause a GLUT1DS-like symptoms, either by themselves or indirectly by disrupting SLC2A1 function.77,78

**DIAGNOSIS AND INITIAL MANAGEMENT OF GLUT1DS PATIENTS**

Based on the data above, the following approach is proposed for the diagnosis and initial management of GLUT1DS patients (Figure 4).

**SPECIFIC TREATMENT**

The treatment of choice for GLUT1DS is the KD, a high-fat diet that induces a metabolic shift to nutritional ketosis. Increased ketone bodies in the blood, replace glucose as a carbohydrates and energy source for the CNS.79,80

The ketogenic diet therapy (KDT) should be initiated as soon as possible to obtain the best results even in the absence of a confirmatory molecular test.21,22,81,82 A recent review on the efficacy of KDT in 270 GLUT1DS patients showed that epilepsy improved in 83% and that this effect was associated with age at treatment onset.83

**Table 1. General characteristics of the cerebrospinal fluid obtained from 157 patients with GLUT1DS**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell count</td>
<td>Within the laboratory reference range</td>
</tr>
<tr>
<td>Protein levels</td>
<td>Within the laboratory reference range</td>
</tr>
<tr>
<td>Glycorrhachia</td>
<td>In the 16.2 to 50.2 mg/dL range (most &lt; 40 mg/dL)</td>
</tr>
<tr>
<td>CSF/blood glucose ratio</td>
<td>In the 0.19 to 0.59 range (most &lt; 0.4)</td>
</tr>
<tr>
<td>Lactic acid</td>
<td>Decreased or within the laboratory reference range</td>
</tr>
</tbody>
</table>

CSF/blood glucose ratio: the relationship of the glucose level in the cerebrospinal fluid and in peripheral blood.
Similarly, movement disorders and neurocognitive disorders also showed significant improvement with the KDT.23,31,59

Although a recent consensus on the use of the KDT for drug-resistant epilepsy has been published, there are specific considerations for the management of GLUT1DS patients with this approach (Table 2).84

The classic KD and the modified Atkins diet (MAD) have shown to be highly effective in the management of seizures resulting in a significant decrease in 80% and a reduction in the use of antiseizure medication in 64% of the patients.22

The classic KD generates high levels of ketosis and is preferred in young children, especially those under 3 years of age.23 In adolescents and adults, the MAD may be indicated to improve adherence, compliance, and quality of life. The low glycemic index diet is not recommended because it provides very low ketones levels and there is no evidence of its benefit for GLUT1DS.81

Regarding the safety, studies show that most patients do not develop adverse effects.83 Perhaps, the most frequently observed complication is failure to adhere to the diet in the long term.83

Treatment duration may be until adolescence and even into adulthood. To prevent long-term adverse effects of the diet, close nutritional and metabolic follow-up by specialists is advised.85

Regardless of the high efficacy that the KDT has demonstrated for the management of GLUT1DS, a certain percentage of these patients do not respond in terms of seizure and abnormal movement control, or achieving cognitive improvement.83,86 Therefore, different treatments are being evaluated as potential complements to the KD. One of them is the triheptanoin, a

---

**Figure 4. Diagnosis and initial management of GLUT1DS patients**

**1- Clinical manifestations suggestive of GLUT1 deficiency**
- Drug-resistant epilepsy of early onset, associated or not with abnormal movements.
- Early onset absence epilepsy (< 4 years old).
- Myoclonic atonic epilepsy.
- Complete seizure control with KD in a patient with drug-resistant epilepsy.
- Continuous movement disorders: ataxia, dystonia, spasticity without a clear etiology.
- Abnormal paroxysmal movements (particularly suggestive eye-head movements).

**2- Cytochemistry of CSF:**
- Preparation for the LP: 4- to 6-hour fasting.
- Measurement of fasting blood glucose levels.
- Cytochemical panel compatible with GLUT1DS:
  - Cells: normal.
  - Protein levels: normal.
  - Glycorrhachia: 16–50 mg/dL (most < 40 mg/dL).
  - CSF/blood glucose ratio < 0.6.
  - Normal or decreased CSF lactic acid levels.

**3A- Start of ketogenic diet**
(start even before the molecular study has been completed)

**3B- Molecular study**
- Sanger sequencing of the SLC2A1 gene.
- MLPA (copy number variants).

Identification of pathogenic sequence variant

**4- Family segregation analysis and genetic counseling**

---

KD: ketogenic diet
CSF: cerebrospinal fluid.
LP: lumbar puncture
CSF/blood glucose ratio: the relationship of the glucose level in the cerebrospinal fluid and in peripheral blood.
MLPA: multiplex ligation-dependent probe amplification.
synthetic triglyceride considered as a substrate to provide Krebs Cycle intermediates that cannot be supplied by glucose. This drug showed encouraging initial results when evaluated in small cohorts of patients, particularly in controlling the number and duration of motor and non-motor paroxysmal events.87–89 However, a subsequent clinical trial did not show clinical efficacy in terms of seizure and movement disorder control.90

Another approach are oral ketones and ketone esters, which, although widely available on the market, have not been recommended for use in GLUT1DS.

A number of small molecules have been a source of interest due to their ability to enhance GLUT1 activity, such as alpha lipoic acid (thioctic acid), insulin-like growth factor-1 (IGF-1), hypoxia-inducible factor 1 alpha (HIF-1alpha), bone morphogenic protein 2 (BMP-2), and fibroblast growth factor 21 (FGF21).91

Lastly, gene therapy holds great promise for improving the quality of life of these patients in the near future. Promising results have recently been obtained in mouse and pig models treated with recombinant adenoviral vectors carrying a functional copy of the SLC2A1 gene.92,93

**CONCLUSION**

GLUT1 deficiency syndrome has a broad clinical spectrum; however, there are manifestations that are highly suggestive of the disease, such as abnormal eye-head movements and drug-resistant seizures that begin early in life regardless of whether or not they are associated with abnormal movements.

The diagnosis is made based on CSF glucose levels in relation to blood glucose, and is confirmed by a comprehensive study of the SLC2A1 gene. In cases in which the latter is positive, it will be extended to the parents of the index case in order to provide adequate family genetic counseling.

In the presence of a strong clinical suspicion, KDT should be initiated early, as it improves long-term prognosis, even prior to molecular confirmation, because the latter may take time or be negative in a small number of patients.

Early diagnostic suspicion, together with an adequate clinical characterization and the availability of the SLC2A1 gene testing are crucial to reduce the time to diagnosis and accelerate the implementation of the most effective treatment.

Currently, in Argentina no statistical data on GLUT1DS are available; therefore, a national survey should be conducted to better understand so as to know with certainty what the situation of this disease in our country.

**REFERENCES**


### Table 2: Comparison of indications and treatment recommendations with ketogenic therapy for neonatal drug-resistant epilepsy and Glut1 deficiency syndrome

<table>
<thead>
<tr>
<th>Criterion</th>
<th>KD for neonatal drug-resistant epilepsy</th>
<th>KD for GLUT1DS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indication:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epilepsy</td>
<td>Insufficient seizure control after 2 or more AEDs</td>
<td>First line of treatment</td>
</tr>
<tr>
<td>Movement disorder</td>
<td>Not indicated</td>
<td>First line of treatment</td>
</tr>
<tr>
<td>Psychomotor development</td>
<td>Not indicated</td>
<td>First line of treatment</td>
</tr>
<tr>
<td><strong>Treatment:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initiation</td>
<td>Optional</td>
<td>At diagnosis, at any age, as soon as possible</td>
</tr>
<tr>
<td>Duration</td>
<td>2 years or longer</td>
<td>Until adulthood</td>
</tr>
<tr>
<td>Ketosis and ketogenic ratio</td>
<td>Variable</td>
<td>The highest tolerable rate</td>
</tr>
<tr>
<td>LGID</td>
<td>Optional</td>
<td>Not recommended</td>
</tr>
<tr>
<td>Ketosis monitoring</td>
<td>In urine or blood</td>
<td>In blood</td>
</tr>
<tr>
<td>Measure carnitine levels</td>
<td>Optional</td>
<td>Recommended</td>
</tr>
<tr>
<td>Adverse effects monitoring</td>
<td>Recommended</td>
<td>Mandatory</td>
</tr>
</tbody>
</table>

KD: ketogenic diet
AEDs: antiepileptic drugs
LGID: low-glycemic index diet


